These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 2953546)
21. Synthesis and expression of a gene from kringle-2 domain of tissue plasminogen activator in E. coli. Hua ZC; Fu HL; Chen YH; Yu RR; Wang J; Zhu DX Sci China B; 1994 Jun; 37(6):667-76. PubMed ID: 7917003 [TBL] [Abstract][Full Text] [Related]
22. Activation of human plasminogen by recombinant staphylokinase. Trieu T; Behnke D; Gerlach D; Tang J Methods Enzymol; 1993; 223():156-67. PubMed ID: 8271950 [No Abstract] [Full Text] [Related]
23. Effects of structural modifications on the properties of tissue plasminogen activator (tPA). Wallén P; Cheng XF; Ohlsson PI Adv Exp Med Biol; 1990; 281():185-94. PubMed ID: 2129368 [No Abstract] [Full Text] [Related]
25. High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli. Sisk WP; Davis GL; Kingsley D; Chiu AT; Reilly TM Gene; 1990 Dec; 96(2):305-9. PubMed ID: 2269442 [TBL] [Abstract][Full Text] [Related]
26. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A; Knockaert I; Declerck PJ Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525 [TBL] [Abstract][Full Text] [Related]
27. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man. Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805 [TBL] [Abstract][Full Text] [Related]
28. The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275. Higgins DL; Lamb MC; Young SL; Powers DB; Anderson S Thromb Res; 1990 Feb; 57(4):527-39. PubMed ID: 2139248 [TBL] [Abstract][Full Text] [Related]
30. Proteolytically induced variations in the enzymatic properties of tissue plasminogen activator. Activations, inactivations and reactivations. Norrman B; Pohl G; Jörnvall H; Wallén P Eur J Biochem; 1986 Aug; 159(1):7-13. PubMed ID: 2943592 [TBL] [Abstract][Full Text] [Related]
31. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain. Rydzewski A; Castellino FJ Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682 [TBL] [Abstract][Full Text] [Related]
32. Disulfide pairing of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli. Vlahos CJ; Wilhelm OG; Hassell T; Jaskunas SR; Bang NU J Biol Chem; 1991 Jun; 266(16):10070-2. PubMed ID: 1645336 [TBL] [Abstract][Full Text] [Related]
33. The cationic locus on the recombinant kringle 2 domain of tissue-type plasminogen activator that stabilizes its interaction with omega-amino acids. De Serrano VS; Castellino FJ Biochemistry; 1992 Dec; 31(47):11698-706. PubMed ID: 1332768 [TBL] [Abstract][Full Text] [Related]
34. Vector pPLEX for expression of nonfusion polypeptides in Escherichia coli. Sczakiel G; Maeda K Methods Enzymol; 1993; 217():3-11. PubMed ID: 8474336 [No Abstract] [Full Text] [Related]
35. Serpin-resistant mutants of human tissue-type plasminogen activator. Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599 [TBL] [Abstract][Full Text] [Related]
36. Primary structure of N-linked carbohydrate chains of a human chimeric plasminogen activator K2tu-PA expressed in Chinese hamster ovary cells. Bergwerff AA; van Oostrum J; Asselbergs FA; Bürgi R; Hokke CH; Kamerling JP; Vliegenthart JF Eur J Biochem; 1993 Mar; 212(3):639-56. PubMed ID: 8462541 [TBL] [Abstract][Full Text] [Related]
37. Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-tPA derivative. Berg DT; Grinnell BW Biochem Biophys Res Commun; 1991 Sep; 179(3):1289-96. PubMed ID: 1930175 [TBL] [Abstract][Full Text] [Related]
38. Direct identification of lysine-33 as the principal cationic center of the omega-amino acid binding site of the recombinant kringle 2 domain of tissue-type plasminogen activator. De Serrano VS; Sehl LC; Castellino FJ Arch Biochem Biophys; 1992 Jan; 292(1):206-12. PubMed ID: 1309292 [TBL] [Abstract][Full Text] [Related]
39. Laboratory and clinical experience with recombinant plasminogen activator. Builder SE; Grossbard E Prog Clin Biol Res; 1986; 211():303-13. PubMed ID: 3083430 [No Abstract] [Full Text] [Related]
40. The production of improved tissue-type plasminogen activator in Escherichia coli. Mattes R Semin Thromb Hemost; 2001 Aug; 27(4):325-36. PubMed ID: 11547355 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]